University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial

Simple item page
dc.contributor.authorRECOVERY Collaborative Group
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Evaluationen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.date.accessioned2020-12-02T11:47:00Z
dc.date.available2020-12-02T11:47:00Z
dc.date.issued2020-10-24
dc.descriptionAcknowledgments Above all, we thank the thousands of patients who participated in this study. We also thank the many doctors, nurses, pharmacists, other allied health professionals, and research administrators at 176 National Health Service (NHS) hospital organisations across the UK, supported by staff at the National Institute for Health Research (NIHR) Clinical Research Network, NHS DigiTrials, Public Health England, UK Department of Health and Social Care, Intensive Care National Audit & Research Centre, Public Health Scotland, National Records Service of Scotland, Secure Anonymised Information Linkage at University of Swansea, and the NHS in England, Scotland, Wales, and Northern Ireland. The RECOVERY trial is supported by a grant to the University of Oxford (Oxford, UK) from UK Research and Innovation and NIHR (MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill & Melinda Gates Foundation, the UK Department for International Development, Health Data Research UK, the Medical Research Council (MRC) Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant from the UK MRC (MC_UU_0002/14) and an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by NIHR Nottingham Biomedical Research Centre. Abbvie contributed some supplies of lopinavir–ritonavir for use in this study. Tocilizumab was provided free of charge for this study by Roche. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health and Social Care. The authors have no conflict of interest or financial relationships relevant to the submitted work to disclose. No form of payment was given to anyone to produce the manuscript. All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The Nuffield Department of Population Health at the University of Oxford has a staff policy of not accepting honoraria or consultancy fees directly or indirectly from industry.en
dc.description.statusPeer revieweden
dc.format.extent8
dc.format.extent568345
dc.identifier180887392
dc.identifier4226ee5b-b9d2-4ea9-b823-85b1ac1bce57
dc.identifier33031764
dc.identifier85093696635
dc.identifier.citationRECOVERY Collaborative Group 2020, 'Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial', The Lancet, vol. 396, no. 10259, pp. 1345-1352. https://doi.org/10.1016/S0140-6736(20)32013-4en
dc.identifier.doi10.1016/S0140-6736(20)32013-4
dc.identifier.iss10259en
dc.identifier.issn0140-6736
dc.identifier.otherORCID: /0000-0002-1397-4272/work/84568299
dc.identifier.otherPubMedCentral: PMC7535623
dc.identifier.otherORCID: /0000-0003-3812-7026/work/188766607
dc.identifier.urihttps://hdl.handle.net/2164/15436
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85093696635&partnerID=8YFLogxKen
dc.identifier.vol396en
dc.language.isoeng
dc.relation.ispartofThe Lanceten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectDrug Combinationsen
dc.subjectFemaleen
dc.subjectHospitalizationen
dc.subjectHumansen
dc.subjectLopinavir/therapeutic useen
dc.subjectMaleen
dc.subjectRitonavir/therapeutic useen
dc.subjectTreatment Outcomeen
dc.subjectCOVID-19 Drug Treatmenten
dc.subjectR Medicineen
dc.subjectGeneral Medicineen
dc.subjectMedical Research Council (MRC)en
dc.subjectMC_UU_0002/14en
dc.subjectNational Institute for Health Research (NIHR)en
dc.subjectMC_PC_19056en
dc.subjectNIHR-SRF-2015-08-001en
dc.subjectSupplementary Dataen
dc.subject.lccRen
dc.titleLopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trialen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Recovery_et_al_TheLan_LopinavirRitonavirInPatients_VoR.pdf
Size:
555.02 KB
Format:
Adobe Portable Document Format
Download

Collections

All research